New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC
Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shares his expert opinion on the importance of the phase III IMbrave150 trial, which evaluated a targeted therapy combination in patients with hepatocellular carcinoma.<br />
Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell,shares his expert opinion on the importance of the phase III IMbrave150 trial (NCT03434379), which evaluated a targeted therapy combination in patients with hepatocellular carcinoma (HCC).
The IMbrave150 trialis interesting because it allows the field to move beyond sorafenib (Nexavar) and nivolumab (Opdivo), 2 targeted agents that have been approved by the FDA under certain indications for HCC, says Saif. Because HCC is an intense disease, it is sometimes necessary to use more than 1 drug to treat the disease. In IMbrave150, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) is compared to sorafenib in patients with untreated locally advanced or metastatic HCC.
TMLI Trial Shows Potential in Relapsed/Refractory Leukemia
October 2nd 2024In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.
Read More
